Tucson, United States
On one side, they offer children who have a rare disease—and an inconclusive whole genome assay—another chance at a diagnosis. A majority of families who order a whole genome test do not receive their much-needed diagnosis and are rarely provided with clear follow-up options. On the other side of the market, they use the genomic data collected to identify orphan drug leads and partner with biopharma to create personalized medicines.
A timely and accurate diagnosis transforms the lives of children with rare diseases. Lodestar’s mission is to create a world in which every child can expect a diagnosis. The startup was founded in 2023 and is headquartered in the United States. Currently, there is no publicly available information regarding their last investment and the associated investors.
